Genetic diagnostics firm GeneDx reported a strong Q2 2025 with 49% revenue growth year-over-year driven by whole-exome and whole-genome testing. The company achieved $102.7 million in quarterly revenues, surpassing analyst expectations, and raised full-year revenue guidance to $400–415 million. GeneDx is targeting market expansion in general pediatrics following updated AAP guidelines recommending genomic sequencing as first-tier tests for developmental delays. The company also improved reimbursement rates, contributing to profitability and sustained growth.